Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Cilastatin in Healthy Volunteers
NCT03595189Phase 1Completed
- Sponsor
- Spherium Biomed
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cilastatin in acute kidney injury (AKI) (4 arms), sponsored by Spherium Biomed. Primary endpoints: Number of subjects with adverse events (AEs) and serious adverse events (SAEs) at 7 days, Changes in Heart rate values at 7 days and 6 more. Started Jun 2018; status: completed.
02
Drugs
cilastatin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03595189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595189.